Comparison of plasmin with recombinant tissue-type plasminogen activator in lysis of cerebral thromboemboli retrieved from patients with acute ischemic stroke

Stroke

Volumn 42, Issue 8, 2011, Pages 2222-2228

  Marder, Victor J ^a   Blinc, Ales ^b   Gruber, Theresa ^b   Tratar, Gregor ^a   Sabovic, Miso ^b   Starkman, Sidney ^a   Jahan, Reza ^a   Duckwiler, Gary ^a   Vinuela, Fernando ^a   Tateshima, Satoshi ^a   Liebeskind, David ^a   Ovbiagele, Bruce ^a   Ali, Letisha ^a   Kim, Doojin ^a   Gonzalez, Nestor ^a   Vespa, Paul M ^a   Saver, Jeffrey L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

embolic stroke; thrombolysis

Indexed keywords

ALTEPLASE; D DIMER; PLASMIN;

ARTICLE; BLOOD CLOT LYSIS; BRAIN ISCHEMIA; CLINICAL ARTICLE; DRUG EXPOSURE; EX VIVO STUDY; HUMAN; INCUBATION TIME; INTERNAL CAROTID ARTERY; MIDDLE CEREBRAL ARTERY; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; THROMBUS;

AGED; BRAIN ISCHEMIA; FEMALE; FIBRINOLYSIN; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; STROKE; THROMBOEMBOLISM; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 79961206815     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.609198     Document Type: Article

References (22)

1. The National Institute of Neurological Disorders and Stroke rtPA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T, Schneider D, von Kummer R, Wahlgren N, Toni D; for the ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
3. Marder VJ, Landskroner K, Novokhatny V, Zimmerman TP, Kong M, Kanouse JJ, Jesmok G. Plasmin induces local thrombolysis without causing hemorrhage: a comparison with tissue plasminogen activator in the rabbit. Thromb Haemost. 2001;86:739-745. (Pubitemid 32834181)
4. Stewart D, Kong M, Novokhatny V, Jesmok G, Marder VJ. Distinct dose-dependent effects of plasmin and tPA on coagulation and hemorrhage. Blood. 2003;101:3002-3007. (Pubitemid 36857987)
5. Marder VJ. Pre-clinical studies of plasmin: superior benefit-to-risk ratio of plasmin compared to tissue plasminogen activator. Thromb Res. 2008; 122(suppl 3):S9-S15.
6. Marder VJ, Novokhatny V. Direct fibrinolytic agents: biochemical attributes, pre-clinical foundation and clinical potential. J Thromb Haemost. 2010;8:433-444.
7. Shlansky-Goldberg RD, Matsumoto AH, Baumbach GA, Siegel JB, Raabe RD, Murphy TP, Deng C, Ray Dawkins J, Marder VJ. A firstin-human Phase I trial of locally delivered human plasmin for hemodialysis graft occlusion. J Thromb Haemost. 2008;6:944-950. (Pubitemid 351689915)
8. Jahan R, Stewart D, Vinters HV, Yong W, Vinuela F, Vandeberg P, Marder VJ. Middle cerebral artery occlusion in the rabbit using selective angiography: application for assessment of thrombolysis. Stroke. 2008; 39:1613-1615.
9. Marder VJ, Jahan R, Gruber T, Goyal A, Arora V. Thrombolysis with plasmin: implications for stroke treatment. Stroke. 2010;41(suppl 1):S45-S49.
10. Marder VJ, Chute DJ, Starkman S, Abolian AM, Kidwell C, Liebeskind D, Ovbiagele B, Vinuela F, Duckwiler G, Jahan R, Vespa PM, Selco S, Rajajee V, Kim D, Sanossian N, Saver JL. Analysis of thrombi retrieved from cerebral arteries of patients with acute ischemic stroke. Stroke. 2006;37:2086-2093. (Pubitemid 44309909)
11. Sabovic M, Lijnen HR, Keber D, Collen D. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators. Thromb Haemost. 1989;62:1083-1087. (Pubitemid 20011494)
12. Tratar G, Blinc A, Podbregar M, Kralj E, Balazic J, Sabovic M, Sersa I. Characterization of pulmonary emboli ex vivo by magnetic resonance imaging and ultrasound. Thromb Res. 2007;120:763-771. (Pubitemid 47268048)
13. Bozic M, Blinc A, Stegnar M. D-dimer, other markers of haemostasis activation and soluble adhesion molecules in patients with different clinical probabilities of deep vein thrombosis. Thromb Res. 2002;108: 107-114. (Pubitemid 36184645)
14. Robbie LA, Bennett B, Croll AM, Brown PA, Booth NA. Proteins of the fibrinolytic system in human thrombi. Thromb Haemost. 1996;75: 127-133. (Pubitemid 26051206)
15. Novokhatny V, Taylor K, Zimmerman TP. Thrombolytic potency of acid-stabilized plasmin: superiority over tissue-type plasminogen activator in an in vitro model of catheter-assisted thrombolysis. J Thromb Haemost. 2003;1:1034-1041.
16. Van Loon BJP, Rijken DC, Brommer EJP, van der Maas APC. The amount of plasminogen, tissue-type plasminogen activator and plasminogen activator inhibitor type 1 in human thrombi and the relation to ex-vivo lysibility. Thromb Haemost. 1992;67:101-105.
17. Collen D, Wiman B. Fast-acting plasmin inhibitor in human plasma: editorial review. Blood. 1978;51:563-569. (Pubitemid 8313139)
18. Harpel PC. Alpha-2-plasmin inhibitor and alpha-2-macroglobulinplasmin complexes in plasma. J Clin Invest. 1981;68:46-55.
19. Lewandowski CA, Frankel M, Tomsick TA, Broderick J, Frey J, Clark W, Starkman S, Grotta J, Spilker J, Khoury J, Brott T; EMS Bridging Trial Investigators. Combined intravenous and intra-arterial rtPA versus intra-arterial therapy of acute ischemic stroke. Emergency management of stroke (EMS) bridging trial. Stroke. 1999;30:2598-2605.
20. Sabovic M, Lijnen HR, Keber D, Collen D. Correlation between progressive adsorption of plasminogen to blood clots and their sensitivity to lysis. Thromb Haemost. 1990;64:4504.
21. Blinc A, Francis CW. Transport processes in fibrinolysis and fibrinolytic therapy. Thromb Haemost. 1996;76:481-491. (Pubitemid 26371997)
22. Bajd F, Vidmar J, Blinc A, Sersa I. Microscopic clot fragment evidence of biochemo-mechanical degradation effects in thrombolysis. Thromb Res. 2010;126:137-143.